Why treatments do(n't) work in vitiligo: An autoinflammatory perspective

Area of Science:

• Dermatology
• Immunology
• Pathophysiology

Background:

• Vitiligo is a difficult-to-treat skin depigmentation disorder impacting quality of life.
• It is frequently associated with other autoimmune conditions.
• Current treatments like topical corticosteroids, calcineurin inhibitors, and UVB therapy show variable efficacy, with resistance being common.

Purpose of the Study:

• To review the underlying mechanisms of vitiligo.
• To correlate these mechanisms with the success or failure of various clinical trial treatments.
• To guide future research and rationalize treatment options for vitiligo.

Main Methods:

• Literature review of current therapeutic options for vitiligo.
• Analysis of the pathophysiology of vitiligo.
• Correlation of disease mechanisms with treatment outcomes in clinical trials.

Main Results:

• Current vitiligo treatments, including topical corticosteroids, topical calcineurin inhibitors, and UVB therapy, have variable results.
• Systemic corticosteroids are effective but limited by safety concerns.
• Tumor Necrosis Factor-alpha (TNF-α) inhibitors have shown paradoxical or failed effects despite elevated TNF-α levels in vitiligo lesions.

Conclusions:

• Understanding vitiligo pathophysiology is crucial for developing effective treatments.
• The review provides insights into why certain treatments succeed or fail.
• This knowledge can rationalize current therapeutic strategies and direct future research for vitiligo.